

Novartis PARALLAX data provides further evidence of the potential benefit of Entresto® in patients with HFpEF

Aug 30, 2020

- *PARALLAX met one of its co-primary endpoints, showing a significant reduction in NT-proBNP with Entresto (sacubitril/valsartan) compared to individualized medical therapy (IMT) at 12 weeks¹; no significant difference observed in other co-primary endpoint (6-minute walk distance) or secondary endpoints compared with IMT¹*
- *A post-hoc analysis suggested Entresto reduced the risk of heart failure events leading to hospitalization over 24 weeks; an exploratory analysis suggested a lesser decline in eGFR, a measure of renal function, over 24 weeks with use of Entresto¹*
- *The overall benefit-risk profile of Entresto demonstrated in PARALLAX was comparable to the active-controlled PARAGON-HF trial and remains positive¹*

East Hanover, August 30, 2020 — Novartis today announced full results from its active-controlled PARALLAX study, further investigating the potential benefit of Entresto (sacubitril/valsartan) in patients with heart failure with preserved ejection fraction (HFpEF), a life-threatening condition with no approved treatment.²⁻⁴ These new study results were presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology.

PARALLAX was a 24-week prospective, randomized, active-controlled, double-blind multi-center clinical trial of patients with chronic HFpEF (EF>40%), examining the effects of Entresto compared to individualized medical therapy (IMT), which could consist of the ACE inhibitor enalapril, the ARB valsartan, or placebo.¹

For the co-primary endpoint, change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at week 12, Entresto significantly reduced NT-proBNP, an important prognostic biomarker in heart failure, by a 16% (adjusted geometric mean ratio: 0.84; 95% CI: 0.80, 0.88; $p<0.0001$) greater extent compared to individualized medical therapy (IMT).^{1,5} The study did not show a statistically significant difference compared with IMT in the functional co-primary endpoint, 6-minute walk distance at week 24 (adjusted mean difference -2.5 m, 95% CI: -8.5, 3.5 m; $p=0.42$) or in secondary endpoints such as change in Kansas City Cardiomyopathy Questionnaire (KCCQ-23) clinical summary score, New York Heart Association (NYHA) class or Short Form-36 (SF-36) physical component clinical summary score.¹

Data from a post-hoc analysis suggest patients in the Entresto group had a lower risk of heart failure events leading to hospitalization over 24 weeks (HR (95% CI): 0.49 (0.30,0.81)).¹ This post-hoc analysis utilized cardiac failure events leading to hospitalization that were reported as adverse events and were not adjudicated.¹ A prespecified exploratory analysis suggested estimated glomerular filtration rate (eGFR) declined less in the Entresto group over 24 weeks (adjusted mean difference (95% CI): 1.10 mL/min/1.73 m² (0.02, 1.99)) compared to IMT.¹ The overall benefit-risk profile of Entresto demonstrated in PARALLAX was comparable to what was seen in the active-controlled PARAGON-HF trial, the largest trial completed in

patients with HFpEF and remains positive.^{1,6,7}

“PARALLAX adds to the growing body of evidence highlighting the potential benefits of Entresto in HFpEF, a life-threatening condition that affects about 3 million people in the US and lacks approved treatments,” said David Soergel, M.D., Global Head of Cardiovascular, Renal and Metabolic Drug Development at Novartis. “The findings, which build on the PARAGON-HF and PARAMOUNT trials, confirm the effect of Entresto on lowering NT-proBNP, a diagnostic and prognostic marker of heart failure. Post-hoc analyses also suggested a lowered risk of heart failure related hospitalizations, one of the most burdensome complications of the illness. We are committed to working with FDA on the potential approval of Entresto as the first-ever medicine for HFpEF in our efforts to reimagine heart failure treatment.”

In June the FDA accepted the supplemental New Drug Application (sNDA) for use of Entresto in heart failure patients with HFpEF. Currently, Entresto is an approved treatment for patients with HFrEF,⁸ also known as systolic heart failure, which is typically defined as ejection fraction less than 40%.⁹ This is based on its superiority to the angiotensin-converting enzyme (ACE) inhibitor enalapril, an active comparator, in reducing cardiovascular death and heart failure hospitalizations, as demonstrated in the PARADIGM-HF trial.¹⁰ Entresto is a first-choice therapy that helps improve the heart’s ability to pump blood to the body in patients with HFrEF.^{8,5}

About Entresto for heart failure with reduced ejection fraction

Entresto (sacubitril/valsartan) is a prescription medicine used to reduce the risk of cardiovascular death and heart failure hospitalization in adults with long-lasting (chronic) heart failure (HFrEF).⁸ Entresto is usually used with other heart failure therapies in place of an angiotensin-converting enzyme (ACE) inhibitor or other angiotensin II receptor blocker (ARB) therapy.⁸ Entresto is a twice-a-day prescription medicine that works by enhancing the beneficial neurohormonal systems (natriuretic peptide system) while simultaneously inhibiting the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS).^{8,11} Most other heart failure medicines only block the harmful effects of the overactive RAAS. Entresto contains the neprilysin inhibitor sacubitril and the ARB valsartan.⁸ Entresto film-coated tablets are available in three dosage strengths: 24/26 mg, 49/51 mg and 97/103 mg (sacubitril/valsartan).⁸ These doses are referred to as 50 mg, 100 mg and 200 mg in the clinical trial literature including *The New England Journal of Medicine* publication of the results of PARADIGM-HF.⁸ In adult patients, the target maintenance dose of Entresto is 97/103 mg twice daily as tolerated by the patient.⁸

IMPORTANT SAFETY INFORMATION

Entresto can harm or cause death to an unborn baby. Patients should talk to their doctor about other ways to treat heart failure if they plan to become pregnant. If a patient gets pregnant while taking Entresto, she should tell her doctor right away.

Patients are not to take Entresto if they are allergic to sacubitril or valsartan or any of the ingredients in Entresto; have had an allergic reaction including swelling of the face, lips, tongue, throat or trouble breathing while taking a type of medicine called an ACE inhibitor or ARB; or take an ACE inhibitor medicine. Patients are not to take Entresto for at least 36 hours before or after they take an ACE inhibitor medicine. Patients should talk with their doctor or pharmacist before taking Entresto if they are not sure if they take an ACE inhibitor medicine. Patients are not to take Entresto if they have diabetes and take a medicine that contains aliskiren.

Before they take Entresto, patients should tell their doctor about all of their medical conditions, including if they have kidney or liver problems; or a history of hereditary angioedema; are pregnant or plan to become

pregnant; are breastfeeding or plan to breastfeed. Patients should either take Entresto or breastfeed. They should not do both.

Patients should tell their doctor about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. They should especially tell their doctor if they take potassium supplements or a salt substitute; nonsteroidal anti-inflammatory drugs (NSAIDs); lithium; or other medicines for high blood pressure or heart problems such as an ACE inhibitor, ARB, or aliskiren.

Entresto may cause serious side effects including serious allergic reactions causing swelling of the face, lips, tongue, and throat (angioedema) that may cause trouble breathing and death. Patients are to get emergency medical help right away if they have symptoms of angioedema or trouble breathing. Patients are not to take Entresto again if they have had angioedema while taking Entresto. People who are black or who have had angioedema may have a higher risk of having angioedema if they take Entresto. Entresto may cause low blood pressure (hypotension). Patients are to call their doctor if they become dizzy or lightheaded, or they develop extreme fatigue. Entresto may cause kidney problems or an increased amount of potassium in the blood.

The most common side effects in adults were low blood pressure, high potassium, cough, dizziness, and kidney problems.

Please see full Prescribing Information, including Boxed WARNING available at <http://www.pharma.us.novartis.com/product/pi/pdf/entresto.pdf>

Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

About Novartis

Located in East Hanover, NJ Novartis Pharmaceuticals Corporation – an affiliate of Novartis – is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis employs about 15,000 people in the United States. For more information, please visit <https://www.novartis.us>.

Novartis and Novartis US is on Twitter. Sign up to follow @Novartis at <https://twitter.com/novartisnews> and @NovartisUS at <https://twitter.com/NovartisUS>.

For Novartis multimedia content, please visit <https://www.novartis.com/news/media-library>

For questions about the site or required registration, please contact media.relations@novartis.com.

#

Novartis Media Relations

E-mail: media.relations@novartis.com

Eric Althoff

Jamie Bennett

Head, US Corp & Country External Comms, Director, US Media Relations

Global Media & Corp Communications +1 862 217 3976

Novartis Investor Relations

E-mail: investor.relations@novartis.com

Sloan Simpson +1 862 778 5052

References

1. Shah S, Wachter R, Solomon S, et al. Angiotensin receptor neprilysin inhibition compared with individualized medical therapy for comorbidities in patients with heart failure and preserved ejection fraction - the PARALLAX trial. ESC Virtual Congress 2020.
2. Virani S, Alonso A, Benjamin E, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. *Circulation*. 2020;141:e139-e596. doi: 10.1161/CIR.0000000000000757
3. Shah K, Xu Haolin, Matsouaka R, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. *J Am Coll Cardiol*. 2017;70(20):2476-2486. doi: 10.1016/j.jacc.2017.08.074
4. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Treatment for heart failure: endpoints for drug
5. Yancy C, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*. 2017;136:e137-e161. doi:10.1161/CIR.0000000000000509
6. Solomon S, Rizkala A, Gong J, et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. *JACC Heart Fail*. 2017;5(7):471-482. doi:
7. Solomon S, McMurray J, Anand I, et al. Angiotensin-Neprilysin in Heart Failure with Preserved Ejection Fraction. *N Engl J Med*. 2019;381:1609-1620. doi: 10.1056/NEJMoa1908655.
8. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2020.
9. The American Heart Association Website. Ejection Fraction Heart Failure Measurement. <https://www.heart.org/en/health-topics/heart-failure/diagnosing-heart-failure/ejection-fraction-heart-failure-measurement>. Accessed August 17, 2020.
10. McMurray J, Packer M, Desai A, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. *Circulation* 2014. *N Engl J Med*. 2014; 371:993-1004 DOI: 10.1056/NEJMoa1409077.
11. Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. *Drug Discov Today*. 2012;9(4):e131-e139. doi:10.1016/j.ddstr.2013.11.002

Disclaimer

This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown

risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

Source URL: <https://www.novartis.com/us-en/news/media-releases/novartis-parallax-data-provides-further-evidence-potential-benefit-entresto-patients-hfpef>

List of links present in page

- <https://www.novartis.com/us-en/us-en/news/media-releases/novartis-parallax-data-provides-further-evidence-potential-benefit-entresto-patients-hfpef>
- https://www.novartis.com/us-en/us-en/sites/novartis_us/files/2022-03/entresto_0.pdf
- <https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program>
- <https://www.novartis.com/us-en/us-en/home>
- <https://twitter.com/novartisnews>
- <https://twitter.com/NovartisUS>
- <https://www.novartis.com/news/media-library>
- <mailto:media.relations@novartis.com>
- <mailto:jamie.bennett@novartis.com>
- <mailto:eric.althoff@novartis.com>
- <mailto:investor.relations@novartis.com>
- <https://www.heart.org/en/health-topics/heart-failure/diagnosing-heart-failure/ejection-fraction-heart-failure-measurement>